{"id":"NCT00527787","sponsor":"POZEN","briefTitle":"Evaluating PN 400 (VIMOVO) in Reducing Gastric Ulcers Compared to Non-steroidal Antiinflammatory Drug (NSAID) Naproxen","officialTitle":"6-Month, Phase 3, Randomized, Double-blind, Parallel-group, Controlled, Multi-center Study Evaluate Gastric Ulcer Incidence Following Administration of PN400 or Naproxen in Subjects Who Are at Risk for Developing NSAID-associated Ulcers","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2007-09","primaryCompletion":"2008-10","completion":"2008-10","firstPosted":"2007-09-11","resultsPosted":"2010-12-28","lastUpdate":"2010-12-28"},"enrollment":434,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"DOUBLE","primaryPurpose":"TREATMENT"},"conditions":["Gastric Ulcer"],"interventions":[{"type":"DRUG","name":"PN400 (VIMOVO)","otherNames":["Vimovo"]},{"type":"DRUG","name":"Naproxen","otherNames":["Naprosyn"]}],"arms":[{"label":"PN400","type":"EXPERIMENTAL"},{"label":"Naproxen","type":"ACTIVE_COMPARATOR"}],"summary":"This study uses a randomized, double-blind, controlled design to demonstrate that PN400 (esomeprazole and naproxen) is more effective in reducing the occurrence of gastroduodenal ulcers, dyspepsia, and heartburn in subjects at risk for developing NSAID-associated gastric ulcers compared to naproxen alone.","primaryOutcome":{"measure":"Number of Participants With Gastric Ulcer Confirmed by Endoscopy","timeFrame":"6 months","effectByArm":[{"arm":"PN400 (VIMOVO)","deltaMin":9,"sd":null},{"arm":"Naproxen","deltaMin":50,"sd":null}],"pValues":[{"comp":"OG000 vs OG001","p":"0.001"}]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":null,"exclusionCount":null},"locations":{"siteCount":1,"countries":["United States"]},"refs":{"pmids":[],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":5,"n":218},"commonTop":["Gastritis erosive","Dyspepsia","Gastritis","Erosive duodenitis","Diarrhoea"]}}